HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK’s Proposal For Mouth Spray Nicorette Delayed By FDA Questions On Label

Executive Summary

Glaxo plans to make changes FDA requested in Complete Response letter sent on 18 October, the agency’s deadline for acting on NDA for an oral spray that delivers 1 mg per spray of aqueous buffered nicotine solution for oromucosal use.

You may also be interested in...

E-Cigarette Study Suggests Not Limiting Cessation Research To Smokers Interested In Quitting

JAMA study results could spur additional research with subjects from broader pool of candidates for determining whether ENDS products have potential for approval as NRT products. Studies typically limit participants to consumers who want to quit, but expanding pool to include those not interested could add to research results more instances of successful quitting.

Kanabo Studying Vaping With CBD And Nicotine Mix To Help Smokers Quit Tobacco And Nicotine

Kanabo, with headquarters in London and R&D in Tel Aviv, says its CBD and nicotine formula has advanced in the patent process from being recognized in the UK to being considered for recognition in the US and the EU, a step it calls “the last phase before becoming an internationally approved patent.”

US Firms Warned On Linking Vaping With Wellness

Warnings to five marketers don’t state smoking cessation claims and vaping also aren’t related. Rather providing nicotine replacement therapy, the products identified in the warnings were reported as being marketed with claims including “Fight off tumors and alleviate symptoms of chemotherapy."

Related Content


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts